Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

NCT02822794 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
117
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Gilead Sciences